Genmab — December 2016
-
JNJ statement ved approval: "We are proud of the rapid development and approval of DARZALEX for use earlier in the treatment pathway, but our work does not stop here,” said Peter F. Lebowitz, M.D., Ph.D., Global Oncology Head, Janssen Research & Development, LLC. “We are only starting to uncover the full potential of this compound, and we remain committed to the continued study of daratumumab to more fully understand its utility for patients with multiple myeloma
and other cancer types.” -
-
Kiggede lige hurtigt CMD prøsentationen igennem - og der var lige en slide som jeg ikke havde lagt mærke til. Ved ikke om det har været nævnt herinde tidligere, men man har i 2016 indledt forskningssamarbejde med CiMass, VLiNK Therapeutics og Imm Therapeutics - ikke så vigtigt lige nu, men da spændende hvis det munder ud i mere senere.
-
-
-
Acetylon Presents Early Phase 1a/1b Results for Citarinostat (ACY-241) in Combination with Pomalyst
and Dexamethasone Showing Promising Treatment Responses in Relapsed or Relapsed-and-Refractory Multiple Myeloma http://www.businesswire.com/news/home/20161204005058/en/Acetylon-Presents-Early-Phase-1a1b-Results-Citarinostat -
Prøv linket igen
-
Daratumumab associated with deep clinical response in relapsed, refractory multiple myeloma http://www.healio.com/
-
Tak jkj og GB.
-
Minimal residual disease (MRD) testing has become a standard assessment with the revised International Myeloma Working Group response criteria and was necessitated by the increasing efficacy of new therapies. These two trials are the first to evaluate MRD in the setting of relapsed disease. In the two studies, a high rate of MRD negativity has been observed, which has translated to longer PFS. The results are a testament to the efficacy of the drug in myeloma.
Shaji Kumar, MD
Mayo Clinic
R -
It is amazing to see that we can get MRD negativity in the relapsed space. Both of these combinations were approved in November.
Noopur Raje, MD
Massachusetts General Hospital Cancer Center -
“Daratumumab led to rapid and durable achievement of MRD negativity,” Avet-Loiseau said. “Patients continue to achieve MRD negativity over time. The high rate of MRD negativity may lead to long-term clinical benefit. The magnitude of daratumumab-induced MRD negativity in the relapsed or refractory multiple myeloma setting is unprecedented.” – by Rob Volansky
-
“MRD negativity was consistently higher in patients treated in daratumumab,” Avet-Loiseau said, adding that patients treated with the drug reached MRD negativity as soon as 3 months. “We still see patients achieving MRD negativity.”
High-risk patients also achieved MRD negative status in both studies, according to Avet-Loiseau. Eighteen percent of high-risk patients in the POLLUX study and 14% of those in CASTOR achieved MRD negativity.
“The most important factor in achieving PFS is MRD negati
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind